KRAS and non-small cell lung carcinoma: The KRAS inhibitors sotorasib and adagrasib were approved by the US Food and Drug Administration (FDA) for second-line treatment of KRAS G12C-mutated NSCLC (25, 26) after demonstrating acceptable objective response rates in these patients after failure of standard therapies, including CIT (27, 28).